Seoul, November 12, : , The European Union’s Drug Agency has approved two monoclonal antibodies treatments for Covid-19 — Celltrion’s Rekirona or Regeneron Roche’s Ronapreve.Seoul, Nov 12, 2012 : .The European Union drug agency recommended approval for two monoclonal anti-Covid-19 treatments — Celltrion Rekirona from Celltrion and Regeneron Roche’s Ronapreve.The Committee for Medicinal Products for Human Use (CHMP), which works under the European Medicines Agency (EMA) has recommended the application of South Korean pharma giant Celltrion’s Rekirona in adult patients aged 18 and older, the EMA said in a statement on Friday.
According to EMA, Friday’s statement stated that the Committee for Medicinal Products for Human Use (“CHMP”) which is part of the European Medicines Agency(EMA) recommended Celltrion’s Rekirona for adult patients over 18 years old.In a Friday statement, the European Medicines Agency (EMA), said that the Committee for Medicinal Products for Human Use(CHMP) had recommended Celltrion’s Rekirona be used in adults aged 18 or older by the Committee for Medicinal Products for Human Use.
While the committee backed Regeneron-Roche’s Ronapreve (also known as casirivimab/imdevimab) for treating Covid-19 in adults and adolescents from 12 years of age who do not require supplemental oxygen and who are at increased risk of their disease becoming severe, Yonhap News Agency reported.
Monoclonal antibodies are proteins designed to attach to a specific target, in this case the spike protein of SARS-CoV-2, which the virus uses to enter human cells.
Monoclonal antibody are proteins that attach to one specific target.In this instance, the spike protein from SARS-CoV-2 is the target.
The virus then uses it to infect human cells.Monoclonal antibodies, proteins which attach to a target protein, are proteins that can be used to identify the specific target.
In reaching its conclusion, the CHMP evaluated data from studies showing that treatment with Ronapreve or Regkirona significantly reduces hospitalisation and deaths in Covid-19 patients at risk of severe Covid-19.The CHMP analyzed data from several studies that showed Ronapreve and Regkirona dramatically reduced hospitalizations and deaths among Covid-19 patients who were at high risk for severe Covid-19.
To reach its conclusions, the CHMP reviewed data from studies that indicated Ronapreve/Regkirona treatment significantly reduced hospitalisations and deaths for Covid-19 patients at higher risk.Another study showed that Ronapreve reduces the chance of having Covid-19 if a household member is infected with SARSaCoVa2, the virus that causes Covid-19.
A second study found that Ronapreve decreases the risk of getting Covid-19 in people whose household members are infected by SARSaCoVa2, which is the virus responsible for Covid-19.Ronapreve can reduce the likelihood of developing Covid-19 from an infection by SARSaCoVa2, a virus that causes Covid-19.
Another study also showed Ronapreve could be used to treat Covid-19-like symptoms in households with a member who is sick.
The European Commission, which is authorised to approve medicines in the region, is expected to issue its decision within two months on the CHMP opinion.
It is anticipated that the European Commission will issue its decision on the CHMP opinion within the next two months.Expect the European Commission to make its decision in two months regarding the CHMP opinion.
The approval would mark the first for any Covid-19 treatment in Europe since Gilead’s remdesivir last year.This approval will be the first European Covid-19 treatment since Gilead’s remdesivir in last year.
It would be the first approval for any Covid-19 treatment to Europe after Gilead’s last year remdesivir.
Celltrion is currently conducting a phase three clinical study of Rekirona in 13 countries on 1,315 critically ill Covid-19 patients.
Celltrion currently conducts a Phase 3 clinical trial of Rekirona across 13 countries with 1,315 Covid-19 critically ill patients.Celltrion is conducting phase 3 of the clinical study on Rekirona with 13 patients who are critically ill Covid-19.
In February, Rekirona won the South Korean drug safety agency’s conditional approval, becoming the first locally made treatment for Covid-19.Rekirona was granted conditional approval by the South Korean Drug Safety Agency in February.
This made her the first local treatment for Covid-19.Rekirona, the first treatment locally for Covid-19, was approved by South Korea’s drug safety agency in February.
The drug won its first overseas approval for an emergency application from Indonesia and Brazil, the report said.According to the report, this drug was approved for emergency use in Indonesia and Brazil.
Report said that the drug received its first approval from overseas for an emergency request in Indonesia and Brazil #endorses #Regeneron #Roche #Covid #abort
.
